Kiniksa Pharmaceuticals International, plc
KNSA
Pozycja w akcjach
#2964
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Cena akcji
$79.61
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$6.21B
Zmiana (1 dzień)
1.30%
Zmiana (1 rok)
104.18%
Kraj
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategoria
Healthcare
Zyski dla Kiniksa Pharmaceuticals International, plc (KNSA)
Zyski w Jun 2026 TTM: $114.25M
Według najnowszych raportów finansowych Kiniksa Pharmaceuticals International, plc, obecny zysk firmy wynosi $114.25M. W roku 2023 firma osiągnęła zysk w wysokości $-16.65M, spadek w porównaniu do zysku z roku 2022, który wynosił $11.03M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Kiniksa Pharmaceuticals International, plc od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 954.75% |
HK
|
